Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza

Portola Pharmaceuticals PTLA today announced that it has executed a supply agreement with Lonza for the commercial manufacturing of andexanet alfa. An FDA-designated breakthrough therapy, andexanet alfa is the only recombinant Factor Xa molecule designed to specifically reverse the effects of oral and injectable Factor Xa inhibitors. It is being developed as an antidote for patients receiving one of these anticoagulants who either suffer from a major bleed or require emergency surgery. With this global agreement, Portola has secured two commercial manufacturing contracts in order to supply the global market. CMC Biologics will manufacture andexanet alfa for the expected U.S. launch in 2016. To meet anticipated global demand, Lonza will provide large-scale supply approximately 18-24 months following launch. Lonza is a worldwide leader in global pharmaceutical manufacturing with more than 40 facilities and 10,000 employees worldwide.